Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02529137 · ClinicalTrials.gov registry record

Pivotal Study for Validation of Philips Dx (PDx)

A clinical trial of Pathologic Processes, sponsored by Philips Digital & Computational Pathology.

Completed
Registry status
2,000
Enrollment target
4
Study locations

NCT02529137: Completed study of Pathologic Processes, sponsored by Philips Digital & Computational Pathology.

NCT02529137 is a study of Pathologic Processes that has completed, run by Philips Digital & Computational Pathology. The registered enrollment target is 2,000 participants, above the 741-participant average among 13 other Pathologic Processes trials with a reported enrollment target (170% higher). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02529137, a study of Pathologic Processes, has completed, sponsored by Philips Digital & Computational Pathology.

COMPLETED
Registry status
2,000 participants
Enrollment target
4
Study locations

Study Summary

The primary objective of this study is to show safety and effectiveness of the PDx for In Vitro Diagnostic (IVD) use as an aid to the pathologist to view, review and diagnose digital images of surgical pathology slides.

Primary Outcome

The primary endpoint was the difference in major discordance rates between Manual Optical (MO) and Manual Digital (MD). MO is defined as reading by using optical microscope whereas MD is defined as reading by using PIPS. MO major discordance rate is defined as the proportion of major discordances between the MO diagnosis and the main diagnosis from the total number of readings. MD major discordance rate is defined as the proportion of major discordances between the MD diagnosis and the main dia

Conditions Studied

Study Locations (4)

Maryland

  • Shady Grove Adventist - Silver Spring

Ohio

  • Cleveland Clinic - Cleveland

Texas

  • Miraca Life Sciences - Irving

Virginia

  • University of Virginia - Charlottesville

Trial Details

FieldValue
Enrollment Target 2,000 participants
Start Date 2015-07
Est. Completion 2016-09

What the finished NCT02529137 record still lists

NCT02529137 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 741-participant average among 13 other Pathologic Processes trials with a reported enrollment target (170% higher).

The record links to 1 condition, with Pathologic Processes appearing as the primary indexed condition, and to 0 interventions.

NCT02529137 reports a single indexed study location in Maryland, Ohio, Texas.

Frequently Asked Questions

What is clinical trial NCT02529137 about?

NCT02529137 is a clinical study titled "Pivotal Study for Validation of Philips Dx (PDx)". The primary objective of this study is to show safety and effectiveness of the PDx for In Vitro Diagnostic (IVD) use as an aid to the pathologist to view, review and diagnose digital images of surgical pathology slides.

What is the current status of trial NCT02529137?

This trial is currently completed. The enrollment target is 2,000 participants. The study started on 2015-07. Estimated completion is 2016-09.

What conditions does trial NCT02529137 study?

This clinical trial studies the following conditions: Pathologic Processes.

Who is sponsoring clinical trial NCT02529137?

This trial is sponsored by Philips Digital & Computational Pathology, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02529137 being conducted?

This trial has 4 study locations across Maryland, Ohio, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pathologic Processes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02529137's enrollment target sits among peer trials

2,000 2nd of 13 higher than 11 of 13 other Pathologic Processes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pathologic Processes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001465 · 2,000 participants

    Study of the Disease Process of Lymphangioleiomyomatosis

  • NCT00001595 · 2,000 participants

    An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

  • NCT00138931 · 2,000 participants

    Genetics of Cardiovascular and Neuromuscular Disease

  • NCT00288119 · 2,000 participants

    Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02529137, the US trial registry maintained by the National Library of Medicine. NCT02529137 (large enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.